Company Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2003 |
| IPO Date | Sep 28, 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 355 |
| CEO | Steven L. Hoerter |
Contact Details
Address: 200 Smith Street Waltham, Massachusetts 02451 United States | |
| Phone | 781-209-6400 |
| Website | deciphera.com |
Stock Details
| Ticker Symbol | DCPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001654151 |
| CUSIP Number | 24344T101 |
| ISIN Number | US24344T1016 |
| Employer ID | 20-0299725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven L. Hoerter | President, Chief Executive Officer and Director |
| Thomas Patrick Kelly J.D. | Executive Vice President, Chief Financial Officer and Treasurer |
| Daniel C. Martin | Senior Vice President and Chief Commercial Officer |
| Dr. Matthew L. Sherman M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Kevin Brodbeck Ph.D. | Senior Vice President and Chief Technical Officer |
| Dr. Dashyant Dhanak Ph.D. | Executive Vice President and Chief Scientific Officer |
| Jennifer Larson | Senior Vice President of Finance and Investor Relations |
| Jeffrey M. Held J.D. | Senior Vice President and General Counsel |
| Lisa Amaya Price | Senior Vice President and Chief Human Resources Officer |
| Jama Pitman | Senior Vice President and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2024 | PRER14A | Filing |
| Apr 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |